Seamlessly Expanding a Randomized Phase II Trial to Phase III

A sequential Bayesian phase II/III design is proposed for comparative clinical trials. The design is based on both survival time and discrete early events that may be related to survival and assumes a parametric mixture model. Phase II involves a small number of centers. Patients are randomized between treatments throughout, and sequential decisions are based on predictive probabilities of concluding superiority of the experimental treatment. Whether to stop early, continue, or shift into phase III is assessed repeatedly in phase II. Phase III begins when additional institutions are incorporated into the ongoing phase II trial. Simulation studies in the context of a non-small-cell lung cancer trial indicate that the proposed method maintains overall size and power while usually requiring substantially smaller sample size and shorter trial duration when compared with conventional group-sequential phase III designs.

[1]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[2]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[3]  Richard Simon,et al.  Two-stage selection and testing designs for comparative clinical trials , 1988 .

[4]  N. Willich,et al.  Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  David R. Cox,et al.  A Remark on Censoring and Surrogate Response Variables , 1983 .

[6]  M S Pepe,et al.  Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. , 1994, Statistics in medicine.

[7]  Michael D. Smith,et al.  Adaptive Bayesian Designs for Dose-Ranging Drug Trials , 2002 .

[8]  B. Leupen,et al.  Design and analysis , 1997 .

[9]  D A Berry,et al.  Decision making during a phase III randomized controlled trial. , 1994, Controlled clinical trials.

[10]  D. Cox.  Regression Models and Life-Tables , 1972 .

[11]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[12]  N M Laird,et al.  Mixture models for the joint distribution of repeated measures and event times. , 1997, Statistics in medicine.

[13]  M Zelen,et al.  Comparing the Survival of Two Groups with an Intermediate Clinical Event , 2001, Lifetime data analysis.

[14]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[15]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[16]  F. J. Anscombe.  Sequential Medical Trials , 1963 .

[17]  Margaret S. Pepe,et al.  Inference using surrogate outcome data and a validation sample , 1992 .

[18]  S W Lagakos,et al.  A stochastic model for censored-survival data in the presence of an auxiliary variable. , 1976, Biometrics.

[19]  D A Berry,et al.  A case for Bayesianism in clinical trials. , 1993, Statistics in medicine.

[20]  David L. DeMets,et al.  Design and analysis of group sequential tests based on the type I error spending rate function , 1987 .

[21]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.

[22]  S W Lagakos,et al.  Using auxiliary variables for improved estimates of survival time. , 1977, Biometrics.

[23]  J Whitehead,et al.  Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes , 1999, Biometrics.

[24]  Adrian F. M. Smith,et al.  Sampling-Based Approaches to Calculating Marginal Densities , 1990 .

[25]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[26]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.

[27]  D. Schoenfeld,et al.  Analysing survival in the presence of an auxiliary variable. , 1994, Statistics in medicine.

[28]  Terry M. Therneau,et al.  Optimal two-stage screening designs for survival comparisons , 1990 .

[29]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .